Management of patients with atrial fibrillation: A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association

Circulation

Volumn 93, Issue 6, 1996, Pages 1262-1277

  Prystowsky, Eric N ^b   Benson Jr , D Woodrow ^b   Fuster, Valentin ^b   Hart, Robert G ^b   Kay, G Neal ^b   Myerburg, Robert J ^b   Naccarelli, Gerald V ^b   Wyse, D George ^b  

^a AMERICAN HEART ASSOCIATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN;

ANTICOAGULATION; ATRIOVENTRICULAR CONDUCTION; BRADYCARDIA; CARDIOMYOPATHY; CARDIOVERSION; CATHETER ABLATION; ELECTROCARDIOGRAPHY; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; TORSADE DES POINTES; WOLFF PARKINSON WHITE SYNDROME;

EID: 0029984410     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.6.1262     Document Type: Review

References (155)

1. Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissner MD. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. J Am Coll Cardiol. 1992;19:41A. Abstract.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018-1022.
3. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA. 1985;254:3449-3453.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147:1561-1564.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
6. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, Frye RL. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987;317:669-674.
7. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM, for the CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236-241.
8. Manolio TA, Furberg CD, Rautaharju PM, Siscovick D, Newman AB, Borhani NO, Gardin JM, Tabatznik B. Cardiac arrhythmias on 24-hour ambulatory electrocardiography in older women and men: the Cardiovascular Health Study. J Am Coll Cardiol. 1994; 23:916-925.
9. Vaziri S, Larson M, Benjamin E, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. J Am Coll Cardiol. 1993;21:394A. Abstract.
10. Radford DJ, Izukawa T. Atrial fibrillation in children. Pediatrics. 1977;59:250-256.
11. Belhassen B, Pauzner D, Bleiden L, Sherez J, Zinger A, David M, Muhlbauer B, Laniado S. Intrauterine and postnatal atrial fibrillation in the Wolff-Parkinson-White syndrome. Circulation. 1982; 66:1124-1128.
12. Johnson WH Jr, Dunnigan A, Fehr P, Benson DW Jr. Association of atrial flutter with orthodromic reciprocating fetal tachycardia. Am J Cardiol. 1987;59:374-375.
13. Till J, Wren C. Atrial flutter in the fetus and young infant: an association with accessory connections. Br Heart J. 1992;67:80-83.
14. Prystowsky EN. Tachycardia-induced tachycardia: a mechanism of initiation of atrial fibrillation. In: DiMarco JP, Prystowsky EN, eds. Atrial Arrhythmias: State of the Art. Armonk, NY: Futura Publishing Co; 1995:P81-P95.
15. Benson DW Jr, Dunnigan A, Benditt DG. Follow-up evaluation of infant paroxysmal atrial tachycardia: transesophageal study. Circulation. 1987;75:542-549.
16. Roark SF, McCarthy EA, Lee KL, Pritchett ELC. Observations on the occurrence of atrial fibrillation in paroxysmal supraventricular tachycardia. Am J Cardiol. 1986;57:571-575.
17. Spirito P, Lakatos E, Maron BJ. Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. Am J Cardiol. 1992;69:1217-1222.
18. Greenwood RD, Rosenthal A, Sloss LJ, LaCorte M, Nadas AS. Sick sinus syndrome after surgery for congenital heart disease. Circulation. 1975;52:208-213.
19. Muller GI, Deal BJ, Strasburger JF, Benson DW Jr. Electrocardiographic features of atrial tachycardias after operation for congenital heart disease. Am J Cardiol. 1993;71:122-124.
20. Butto F, Dunnigan A, Overholt ED, Benditt DG, Benson DW Jr. Transesophageal study of recurrent atrial tachycardia after atrial baffle procedures for complete transposition of the great arteries. Am J Cardiol. 1986;57:1356-1362.
21. Perry LW, Hung W. Atrial fibrillation and hyperthyroidism in a 14-year-old boy. J Pediatr. 1971;79:668-671.
22. Short DS. The syndrome of alternating bradycardia and tachycardia. Br Heart J. 1954;16:208-214.
23. Hudson REB. The human pacemaker and its pathology. Br Heart J. 1960;22:153-167.
24. Myerburg RJ, Kessler KM, Castellanos A. Recognition, clinical assessment, and management of arrhythmias and conduction disturbances. In: Schlant RC, Alexander RW, O'Rourke RA, Roberts R, Sonnenblick EH, eds. Hurst's: The Heart. 8th ed. New York, NY: McGraw-Hill; 1994:705-758.
25. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther. 1962;140:183-188.
26. Allessie MA, Lammers WJEP, Bonke FIM, Hollen J. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology and Arrhythmias. Orlando, Fla: Grune & Stratton; 1985:265-276.
27. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
28. Burn JH, Williams EMV, Walker JM. The effects of acetylcholine in the heart-lung preparation including the production of auricular fibrillation. J Physiol. 1955;128:277-293.
29. Giles W, Noble SJ. Changes in membrane currents in bullfrog atrium produced by acetylcholine. J Physiol (Lond). 1976;261: 103-123.
30. Atteul P, Childers R, Cauchemez B, Poveda J, Mugica J, Coumel P. Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability. Int J Cardiol. 1982;2:179-197.
31. Merideth J, Mendez C, Mueller WJ, Moe GK. Electrical excitability of atrioventricular nodal cells. Circ Res. 1968;23:69-85.
32. Hoffman BF, Paes de Carvalho A, deMello WC, Cranefield PF. Electrical activity of single fibers of the atrioventricular node. Circ Res. 1959;7:11-18.
33. Englemann ThW. Boebachtungen und versuche an suspendirten herzen. Pflugers Arch. 1894;56:149-202.
34. Langendorf R. Concealed conduction: the effect of blocked impulses on the formation and conduction of subsequent impulses. Am Heart J. 1948;35:542-552.
35. Moe GK, Abildskov JA. Observations on the ventricular dysrhythmia associated with atrial fibrillation in the dog heart. Circ Res. 1964;14:447-460.
36. Naito M, David D, Michelson EL, Schaffenburg M, Dreifus LS. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J. 1983;106:284-291.
37. Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE, Gallagher JJ, German LD. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563-570.
38. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;69: 1570-1573.
39. Kieny JR, Sacrez A, Facello A, Arbogast R, Bareiss P, Roul G, Demangeat J-L, Brunot B, Constantinesco A. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13:1290-1295.
40. Rodriguez LM, Smeets JLRM, Xie B, de Chillou C, Cheriex E, Pieters F, Metzger J, den Dulk K, Wellens HJJ. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol. 1993;72:1137-1141.
41. Campbell RWF, Smith RA, Gallagher JJ, Pritchett ELC, Wallace AG. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol. 1977;40:514-520.
42. Chen PS, Pressley JC, Tang ASL, Packer DL, Gallagher JJ, Prystowsky EN. New observations on atrial fibrillation before and after surgical treatment in patients with the Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 1992;19:974-981.
43. Sung RJ, Castellanos A, Mallon SM, Bloom MG, Gelband H, Myerburg RJ. Mechanisms of spontaneous alternation between reciprocating tachycardia and atrial flutter-fibrillation in the Wolff-Parkinson-White syndrome. Circulation. 1977;56:409-416.
44. Hurwitz JL, German LD, Packer DL, Wharton JM, McCarthy EA, Wilkinson WE, Prystowsky EN, Pritchett ELC. Occurrence of atrial fibrillation in patients with paroxysmal supraventricular tachycardia due to atrioventricular nodal reentry. Pacing Clin Electrophysiol. 1990;13:705-710.
45. Lab MJ. Contraction-excitation feedback in myocardium: physiological basis and clinical relevance. Circ Res. 1982;50:757-766.
46. Spach MS, Dolber PC, Heidlage JF. Influence of the passive anisotropic properties on directional differences in propagation following modification of the sodium conductance in human atrial muscle: a model of reentry on anisotropic discontinuous propagation. Circ Res. 1988;62:811-832.
47. Fujimura O, Klein GJ, Yee R, Sharma AD. Mode of onset of atrial fibrillation in the Wolff-Parkinson-White syndrome: how important is the accessory pathway? J Am Coll Cardiol. 1990;15: 1082-1086.
48. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. 1979;301:1080-1085.
49. Fananapazir L, Packer DL, German LD, Greer GS, Gallagher JJ, Pressley JC, Prystowsky EN. Procainamide infusion test: inability to identify patients with Wolff-Parkinson-White syndrome who are potentially at risk of sudden death. Circulation. 1988;77:1291-1296.
50. Dreifus LS, Haiat R, Watanabe Y, Arriaga J, Reitman N. Ventricular fibrillation: a possible mechanism of sudden death in patients with Wolff-Parkinson-White syndrome. Circulation. 1971; 43:520-527.
51. Coumel P. Neurogenic and humoral influences of the autonomic nervous system in the determination of paroxysmal atrial fibrillation. In: Atteul P, Coumel P, Janse MJ, eds. The Atrium in Health and Disease. Mount Kisco, NY: Futura Publishing Co; 1989: 213-232.
52. Petersen P, Kastrup J, Videbaek R, Boysen G. Cerebral blood flow before and after cardioversion of atrial fibrillation. J Cereb Blood Flow Metab. 1989;9:422-425.
53. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med. 1987; 106:503-506.
54. Salerno DM, Dias VC, Kleiger RE, Tschida VH, Sung RJ, Sami M, Giorgi LV. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter: the Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1989;63: 1046-1051.
55. Rinkenberger RL, Prystowsky EN, Heger JJ, Troup PJ, Jackman WM, Zipes DP. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation. 1980;62:996-1010.
56. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation. 1990;82:1106-1116.
57. Fenster PE, Comess KA, Marsh R, Katzenherg C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J. 1983;106:501-504.
58. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electro-conversion of atrial fibrillation: a placebo-controlled one-year follow-up study. Eur Heart J. 1988;9:284-290.
59. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett EL. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring: Flecainide Supraventricular Tachycardia Study Group. Circulation. 1989;80:1557-1570.
60. Pritchett ELC, DaTorre SD, Platt ML, McCarville SE, Hougham AJ. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies: the Flecainide Supraventricular Tachycardia Study Group. J Am Coll Cardiol. 1991;17:297-303.
61. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 1988;12:1005-1011.
62. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol. 1989;63:817-819.
63. Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114:539-544.
64. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993;71:558-563.
65. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82: 1932-1939.
66. Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, Brady PM, Kay HR. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol. 1985;6:1402-1407.
67. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol. 1986; 57:124-127.
68. Brodsky MA, Allen BJ, Walker CJ III, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol. 1987;60:572-575.
69. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA. 1992;267: 3289-3293.
70. Lévy S, Lauribe P, Dolla E, Kou W, Kadish A, Calkins H, Pagannelli F, Moyal C, Bremondy M, Schork A, Shyr Y, Das S, Shea M, Gupta N, Morady F. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation. 1992;86:1415-1420.
71. McGovern B, Garan H, Ruskin JN. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. Ann Intern Med. 1986;104:791-794.
72. Gulamhusein S, Ko P, Klein GJ. Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. Am Heart J. 1983;106(pt 1):145-147.
73. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett ELC. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994;89:224-227.
74. Prystowsky EN. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. Clin Cardiol. 1994;17(suppl 2):II-7-II-10.
75. Ejvinsson G, Orinius E. Prodromal ventricular premature beats preceded by a diastolic wave. Acta Mad Scand. 1980;208:445-450.
76. Reynolds EW, Vander Ark CR. Quinidine syncope and the delayed repolarization syndromes. Mod Concepts Cardiovasc Dis. 1976;45:117-122.
77. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992;20:527-532.
78. Selzer A, Wray HW. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation. 1964;30:17-26.
79. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088-1093.
80. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
81. Pritchett ELC, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol. 1991;67:976-980.
82. Crijns HJ, van Gelder IC, Lie KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol. 1988;62:1303-1306.
83. Feld GK, Chen PS, Nicod P, Fleck RP, Meyer D. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol. 1990;66:378-383.
84. Rinkenberger RL, Naccarelli GV, Berns E, Dougherty AH. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia. Am J Cardiol. 1988;62:44D-55D.
85. Williams JM, Ungerleider RM, Lofland GK, Cox JL. Left atrial isolation: new technique for the treatment of supraventricular arrhythmias. J Thorac Cardiovasc Surg. 1980;80:373-380.
86. Defauw JJ, Guiraudon GM, van Hemel NM, Vermeulen FE, Kingma JH, de Bakker JM. Surgical therapy of paroxysmal atrial fibrillation with the corridor operation. Ann Thorac Surg. 1992;53: 564-571.
87. Cox JL. The surgical treatment of atrial fibrillation, IV: surgical technique. J Thorac Cardiovasc Surg. 1991;101:584-592.
88. Haissaguerre M, Gencel L, Fischer B, Le Metayer P, Poquet F, Marcus FI, Clementy J. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 1994;5:1045-1052.
89. Sgarbossa EB, Pinski SL, Maloney JD, Simmons TW, Wilkoff BL, Castle LW, Trohman RG. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome: relevance of clinical characteristics and pacing modalities. Circulation. 1993;88: 1045-1053.
90. Feuer JM, Shandling AH, Messenger JC. Influence of cardiac pacing mode on the long-term development of atrial fibrillation. Am J Cardiol. 1989;64:1376-1379.
91. Lauer MS, Eagle KA, Buckley MJ, DeSanctis RW. Atrial fibrillation following coronary artery bypass surgery. Prog Cardiovasc Dis. 1989;31:367-378.
92. Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol. 1992;69:963-965.
93. Goodman DJ, Rossen RM, Cannom DS, Rider AK, Harrison DC. Effect of digoxin on atrioventricular conduction: studies in patients with and without cardiac autonomic innervation. Circulation. 1975;51:251-256.
94. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990;63:225-227.
95. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol. 1991;18: 891-897.
96. Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med. 1981;94:1-6.
97. Aronow WS, Landa D, Plasencia G, Wong R, Karlsberg RP, Ferlinz J. Verapamil in atrial fibrillation and atrial flutter. Clin Pharmacol Ther. 1979;26:578-583.
98. Reiter MJ, Shand DG, Aanonsen LM, Wagoner R, McCarthy E, Pritchett EL. Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen. Am J Cardiol. 1982;50: 716-721.
99. Product Labeling. Cardiazem Injectable. Kansas City, Mo: Marion Merrell Dow; 1991:(Oct)64114.
100. Anderson S, Blanski L, Byrd RC, Das G, Engler R, Laddu A, Lee R, Rajfer S, Schroeder J, Steck JD, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias: the Esmolol vs Placebo Multicenter Study Group. Am Heart J. 1986; 111:42-48.
101. DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, McGovern B, Scheinman MM, Govier WC. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil - assessment in placebo-controlled, multi-center trials: the Adenosine for PSVT Study Group. Ann Intern Med. 1990;113:104-110.
102. David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44:1378-1382.
103. DiBianco R, Morganroth J, Freitag JA, Ronan JA Jr, Lindgren KM, Donohue DJ, Larca LJ, Chadda KD, Olukotun AY. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J. 1984;108(pt 2):1121-1127.
104. Klein HO, Kaplinsky E. Digitalis and verapamil in atrial fibrillation and flutter: is verapamil now the preferred agent? Drugs. 1986;31:185-197.
105. Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, Elkayam U. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation. 1986;73:316-324.
106. Scheinman MM, Morady F, Hess DS, Gonzalez R. Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. JAMA. 1982;248:851-855.
107. Gallagher JJ, Svenson RH, Kasell JH, German LD, Bardy GH, Broughton A, Critelli G. Catheter technique for closed-chest ablation of the atrioventricular conduction system: a therapeutic alternative for the treatment of refractory supraventricular tachycardia. N Engl J Med. 1982;306:194-200.
108. Kay GN, Bubien RS, Epstein AE, Plumb VJ. Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol. 1988;62(pt 1):741-744.
109. Evans GT Jr, Scheinman MM, Zipes DP, Benditt D, Breithardt G, Camm AJ, el-Sherif N, Fisher J, Fontaine G, Levy S, Prystowsky E, Josephson ME, Morady F, Ruskin J. The Percutaneous Cardiac Mapping and Ablation Registry: summary of results. Pacing Clin Electrophysiol. 1987;10:1395-1399.
110. Langberg JJ, Chin MC, Rosenqvist M, Cockrell J, Dullet N, Van Hare G, Griffin JC, Scheinman MM. Catheter ablation of the atrioventricular junction with radiofrequency energy. Circulation. 1989;80:1527-1535.
111. Williamson BD, Man KC, Daoud E, Niebauer M, Strickberger SA, Morady F. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med. 1994;331:910-917.
112. Feld GK, Fleck RP, Fujimura O, Prothro DL, Bahnson TD, Ibarra M. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation. 1994;90: 2299-2307.
113. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
114. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
115. Feinberg WM, Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearce LA. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch Intern Med. 1990;150:2340-2344.
116. Kempster PA, Gerraty RP, Gates PC. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. Stroke. 1988; 19:955-957.
117. Petersen P, Madsen EB, Brun B, Pedersen F, Gyldensted C, Boysen G. Silent cerebral infarction in chronic atrial fibrillation. Stroke. 1987;18:1098-1100.
118. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med. 1992;116:1-5.
119. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: echocardiographic features of patients at risk. Ann Intern Med. 1992;116:6-12.
120. Asplund K, Carlberg B, Sundstrom G. Stroke in the elderly. Cerebrovascular Diseases. 1992;2:152-157.
121. Boysen G, Nyboe J, Appleyard M, Sorensen PS, Boas J, Somnier F, Jensen G, Schnohr P. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke. 1988;19:1345-1353.
122. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am J Med. 1991;91:156-161.
123. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism: Stroke Prevention in Atrial Fibrillation Investigators. Neurology. 1993;43:32-36.
124. Bogousslavsky J, Van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 1990; 40:1046-1050.
125. Kanter MC, Tegeler CH, Pearce LA, Weinberger J, Feinberg WM, Anderson DC, Gomez CR, Rothrock JF, Helgason CM, Hart RG. Carotid stenosis in patients with atrial fibrillation: prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. Arch Intern Med. 1994;154: 1372-1377.
126. Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol. 1990;65:1112-1116.
127. Flegel KM, Hanley J. Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation. Stroke. 1989;20:1000-1004.
128. Wiener I. Clinical and echocardiographic correlates of systemic embolization in nonrheumatic atrial fibrillation. Am J Cardiol. 1987;59:177.
129. Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol. 1989;63:366-367.
130. Petersen P, Kastrup J, Helweg-Larsen S, Boysen G, Godtfredsen J. Risk factors for thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Arch Intern Med. 1990;150:819-821.
131. Blackshear JL, Pearce LA, Asinger RW, Dittrich HC, Goldman ME, Zabalgoitia M, Rothbart RM, Halperin JL. Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation: Stroke Prevention in Atrial Fibrillation Investigators. Am J Cardiol. 1993;72:840-843.
132. Rosenthal MS, Halperin JL. Thromboembolism in nonvalvular atrial fibrillation: the answer may be in the ventricle. Int J Cardiol. 1992;37:277-282.
133. Zabalgoitia M, Dipeshkumar KG, McPherson D, Mehlman DJ, Talano JV. Spontaneous echo contrast in severe left ventricular dysfunction: a risk factor for thromboembolism. Circulation. 1990; 82(suppl 3):III-109. Abstract.
134. Chimowitz MI, DeGeorgia MA, Poole RM, Hepner A, Armstrong WM. Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke. 1993;24:1015-1019.
135. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25:452-459.
136. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for atrial stunning as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307-316.
137. Black IW, Fatkin D, Sagar KB, Khandheria BK, Leung DY, Galloway JM, Feneley MP, Walsh WF, Grimm RA, Stollberger C, Verhorst PMJ, Klein AL. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: a multicenter study. Circulation. 1994;89:2509-2513.
138. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70:725-733.
139. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-1412.
140. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
141. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1: 175-179.
142. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342: 1255-1262.
143. Prevention of stroke in atrial fibrillation. N Engl J Med. 1990;323: 481-484.
144. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235-246.
145. Miller VT, Pearce LA, Feinberg WM, Rothrock JF, Anderson DC, Hart RG, for the Stroke Prevention in Atrial Fibrillation Investigators. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Neurology. 1996;46:238-240.
146. Stroke Prevention in Atrial Fibrillation Investigators. A differential effect of aspirin for prevention of stroke in atrial fibrillation. Journal of Stroke and Cerebrovasculur Disesses. 1993;3:181-188.
147. D'Olhaberriague L, Hernandez-Vidal A, Molina L, Soler-Singla L, Marrugat J, Pons S, Moral A, Pou-Serradell A. A prospective study of atrial fibrillation and stroke. Stroke. 1989;20:1648-1652.
148. Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW, Blewett DR, Rosner B, Kistler JP, for the BAATAF Investigators. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: the BAATAF study. Am Heart J. 1992;124:1567-1573.
149. Vingerhoets F, Bogousslavsky J, Regli F, Van Melle G. Atrial fibrillation after acute stroke. Stroke. 1993;24:26-30.
150. Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, Boonyakarnkul S, Warlow C. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long-term prognosis. BMJ. 1992;305:1460-1465.
151. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
152. Bjerkclund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208-216.
153. Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol. 1989;63:745-746.
154. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1992;102(suppl 4):426S-433S.
155. Manning WJ, Silverman Dl, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiography facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol. 1995;25: 1354-1361.